Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HX009 in Advanced Malignancies
NCT04097769Phase 1Completed
- Sponsor
- Waterstone Hanxbio Pty Ltd
- Start
- Jun 2019
- Primary completion
- Mar 2021
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HX009 in solid tumor (advanced stage), sponsored by Waterstone Hanxbio Pty Ltd. Primary endpoints: Number of Participants Experiencing Adverse Events and Number of Participants With Dose-Limiting Toxicities. Started Jun 2019; status: completed.
02
Drugs
HX009
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04097769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04097769.